NVP-BHG712
Based on 9 publication(s) in Google Scholar
NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC50 values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 940310-85-0
- Formula: C26H20F3N7O
- Molecular Weight:503.48
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Angiogenesis-Related Compound Library
HY-L088
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
Kinase Inhibitor Library Mini
HY-L009M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) NVP-BHG712
More- Cancer Commun (Lond). 2026 Jun 16.
- J Adv Res. 2026 Feb 21:S2090-1232(26)00176-1. [Abstract]
- Pharmacol Res. 2020 Aug;158:104868. [Abstract]
- Cell Death Dis. 2020 Aug 14;11(8):632. [Abstract]
- Phytomedicine. 2021 Apr:84:153503. [Abstract]
- Sci Rep. 2024 Jan 4;14(1):560. [Abstract]
- bioRxiv. 2026 Apr 18.
- Technical University of Dresden. 2025.
- bioRxiv. 2025 January 18.
Customer Validation & Images
-
WB
-
WB
Biological Activity
IC50: 3.3 nM (EphA2), 3 nM (EphB4)[2].
NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity. The data suggests a close cross talk between the VEGFR and EphR signaling during vessel formation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice arrying chambers[1].
-
Dosage:3, 10 and 30 mg/kg.
-
Administration:P.O. daily for 4 days.
-
Result:Significantly inhibited VEGF stimulated tissue formation and vascularization at doses of daily 3 mg/kg. Administration of 10 mg/kg/kg p.o. was sufficient to reverse VEGF enhanced tissue formation and vessel growth.
Chemical Information
-
CAS No. 940310-85-0
-
Appearance Solid
-
Molecular Weight 503.48
-
Formula C26H20F3N7O
-
Color White to yellow
-
SMILES
CC1=CC=C(C=C1NC2=NC(C3=CC=CN=C3)=NC4=C2C=NN4C)C(NC5=CC=CC(C(F)(F)F)=C5)=O
-
Synonyms
BHG712
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
-
J Adv Res
Identification of a novel EphB4 inhibitor, Sanguinarine, which attenuates β-catenin signaling to inhibit tumor proliferation and migration in lung cancer. [Abstract]2026 Feb 21:S2090-1232(26)00176-1. PMID: 41730417 -
Pharmacol Res
Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner. [Abstract]2020 Aug;158:104868. PMID: 32407961
NVP-BHG712 purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2020 Aug;158:104868. [Abstract]
Protein expression of EphB4, JAK2, p-JAK2, STAT3, and p-STAT3 in HepG2 cells treated with either CTD (2.5 μM), NVP-BHG-712 (1 μM), or the combination of both.
-
Cell Death Dis
Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated β-catenin loss in hepatocellular carcinoma. [Abstract]2020 Aug 14;11(8):632. PMID: 32801343
NVP-BHG712 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Aug 14;11(8):632. [Abstract]
Western blot analysis of HepG2 cells EphB4 expression after NVP-BHG712 treatment. NVP-BHG712treatment decreases in the expression level of EphB4 in HepG2 cells.
-
Phytomedicine
Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer. [Abstract]2021 Apr:84:153503. PMID: 33636580 -
Sci Rep
ADAMTS13 regulates angiogenic markers via Ephrin/Eph signaling in human mesenchymal stem cells under serum-deprivation stress. [Abstract]2024 Jan 4;14(1):560. PMID: 38177376 -
-
-
Solvent & Solubility
DMSO : 31.25 mg/mL (62.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.13 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tröster A, et al. NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. ChemMedChem. 2018 Aug 20;13(16):1629-1633. [Content Brief]
[2]. Martiny-Baron G, et al. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 2010 Sep;13(3):259-67. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9862 mL | 9.9309 mL | 19.8618 mL | 49.6544 mL |
| 5 mM | 0.3972 mL | 1.9862 mL | 3.9724 mL | 9.9309 mL | |
| 10 mM | 0.1986 mL | 0.9931 mL | 1.9862 mL | 4.9654 mL | |
| 15 mM | 0.1324 mL | 0.6621 mL | 1.3241 mL | 3.3103 mL | |
| 20 mM | 0.0993 mL | 0.4965 mL | 0.9931 mL | 2.4827 mL | |
| 25 mM | 0.0794 mL | 0.3972 mL | 0.7945 mL | 1.9862 mL | |
| 30 mM | 0.0662 mL | 0.3310 mL | 0.6621 mL | 1.6551 mL | |
| 40 mM | 0.0497 mL | 0.2483 mL | 0.4965 mL | 1.2414 mL | |
| 50 mM | 0.0397 mL | 0.1986 mL | 0.3972 mL | 0.9931 mL | |
| 60 mM | 0.0331 mL | 0.1655 mL | 0.3310 mL | 0.8276 mL |
Powered by Bioz